Clinical Trials

Developed by Global Kinetics Corporation, the Parkinson’s KinetiGraph (PKG™ or Personal KinetiGraph as it is known in the USA), is an innovative mobile health technology. The PKG™ system provides a continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson’s disease including tremor, bradykinesia and dyskinesia. The PKG™also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.

The PKG™ system includes a wrist-worn movement recording device called the PKG™-Watch, proprietary algorithms and a data-driven report known as the PKG™.

Data is collected continuously by the PKG™-Watch during activities of daily living in the home environment and can be programmed to remind the patient, at their prescribed Parkinson's disease medication times, to register that they’ve taken their Parkinson's disease medication. The PKG™-Watch should be worn by the patient for 7 days.

At the end of the recording period, the data is uploaded for processing. The PKG™ is generated and emailed to the patient’s clinician, graphically and numerically depicting the movement of the patient. The PKG™ shows scores representative of dyskinesia and bradykinesia, compared to controls, throughout the day and from day to day. Other information such as medication compliance, motor fluctuations, immobility, tremor and periods where the PKG™-Watch was not worn are also shown.

An example of a PKG™ main plot showing Dyskinesia Score (DKS) in green and Bradykinesia Score (BKS) in blue

Regulatory Status

The PKG™ system has received regulatory clearance through FDA 510 (k) in the USA, CE mark in Europe and is TGA Class IIa ARTG 236583 listed in Australia.